- Atzumi is an FDA-approved dihydroergotamine nasal powder for acute migraine treatment.
- It utilizes Simple MucoAdhesive Release Technology for rapid absorption.
- FDA approval was supported by key studies demonstrating convenience and portability.
- Atzumi has warnings for serious adverse effects and several contraindications.
Source: Satsuma Pharmaceuticals
